| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | 
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Total Revenue | 36.95B | 37.29B | 35.52B | 31.45B | 24.71B | 18.26B | 
| Gross Profit | 13.35B | 14.43B | 11.50B | 10.58B | 10.46B | 5.77B | 
| EBITDA | 10.93B | 11.52B | 11.69B | 10.36B | 8.11B | 5.63B | 
| Net Income | 7.45B | 7.85B | 7.92B | 7.55B | 5.50B | 3.68B | 
| Balance Sheet | ||||||
| Total Assets | 0.00 | 35.86B | 31.87B | 27.64B | 21.69B | 17.17B | 
| Cash, Cash Equivalents and Short-Term Investments | 15.90B | 15.89B | 13.80B | 11.81B | 9.56B | 8.53B | 
| Total Debt | 0.00 | 1.92B | 2.24B | 1.82B | 1.39B | 732.10M | 
| Total Liabilities | -28.60B | 7.26B | 6.81B | 6.78B | 5.68B | 3.65B | 
| Stockholders Equity | 28.60B | 28.61B | 25.06B | 20.86B | 16.01B | 13.52B | 
| Cash Flow | ||||||
| Free Cash Flow | 0.00 | 7.96B | 6.18B | 4.23B | 4.12B | 3.99B | 
| Operating Cash Flow | 0.00 | 8.12B | 7.01B | 4.87B | 4.83B | 4.37B | 
| Investing Cash Flow | 0.00 | -3.08B | -2.70B | -2.02B | -1.08B | -4.38B | 
| Financing Cash Flow | 0.00 | -4.99B | -4.28B | -3.03B | -3.26B | -1.26B | 
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth | 
|---|---|---|---|---|---|---|---|
| ― | ₹132.81B | 22.48 | ― | 2.52% | 1.68% | -12.95% | |
| ― | ₹313.69B | 38.50 | ― | 0.71% | 17.09% | 21.20% | |
| ― | ₹522.85B | 29.38 | ― | 1.98% | 8.11% | 10.73% | |
| ― | ₹278.14B | 40.11 | ― | 1.20% | 0.29% | 7.17% | |
| ― | ₹345.38B | 51.50 | ― | 1.35% | -1.19% | -17.92% | |
| ― | ₹445.15B | 34.40 | ― | 1.36% | 14.88% | -2.60% | |
| ― | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | 
Tata Elxsi Limited announced the release of an audio recording of their conference call discussing the financial results for the quarter and half-year ending September 30, 2025. This announcement provides stakeholders, including investors and analysts, with insights into the company’s financial performance, potentially impacting their market perceptions and investment decisions.
Tata Elxsi has launched the Bayer Development Centre in Radiology in Pune, India, in collaboration with Bayer. This centre aims to co-develop advanced radiology devices and technology, enhancing early and accurate diagnosis and treatment of critical illnesses. The initiative is expected to accelerate time-to-market, improve cost efficiency, and ensure compliance with regulatory standards. By leveraging Tata Elxsi’s healthcare engineering expertise and the broader Tata and India ecosystems, the collaboration strengthens Bayer’s ability to deliver radiology solutions globally, particularly in the US and EU.